Lopinavir/ritonavir monotherapy as a nucleoside analogue-sparing strategy to prevent HIV-1 mother-to-child transmission: The ANRS 135 PRIMEVA phase 2/3 randomized trial

Clinical Infectious Diseases

Volumn 57, Issue 6, 2013, Pages 891-902

  Tubiana, Roland ^a,b   Mandelbrot, Laurent ^c,d,e   Le Chenadec, Jérome ^c   Delmas, Sandrine ^c,f   Rouzioux, Christine ^e,g   Hirt, Deborah ^e,h   Treluyer, Jean Marc ^e,h   Ekoukou, Dieudonné ⁱ   Bui, Eda ^j   Chaix, Marie Laure ^e,g   Blanche, Stéphane ^e,g   Warszawski, Josiane ^c,f  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSERM   (France)

^c CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^d HÔPITAL LOUIS MOURIER   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f BICÊTRE HOSPITAL   (France)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

^h Service de Virologie ^*  (France)

ⁱ Centre Hospitalier General   (France)

^j HÔPITAL SAINT ANTOINE   (France)

more..

Author keywords

HIV; lopinavir ritonavir; monotherapy; PMTCT; zidovudine

Indexed keywords

LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LIVER ENZYME; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; VIRUS RNA; ZIDOVUDINE;

ADULT; AMNION FLUID ANALYSIS; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; CESAREAN SECTION; CHEMOPROPHYLAXIS; CONFERENCE PAPER; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MATERNAL PLASMA; MEAN CORPUSCULAR VOLUME; MONOTHERAPY; MULTICENTER STUDY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PREGNANT WOMAN; PREMATURE LABOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; UMBILICAL CORD BLOOD; UNSPECIFIED SIDE EFFECT; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS TRANSMISSION; VOMITING;

HIV; LOPINAVIR/RITONAVIR; MONOTHERAPY; PMTCT; ZIDOVUDINE;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LOPINAVIR; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RITONAVIR;

EID: 84883238166     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit390     Document Type: Conference Paper

References (38)

1. Yéni P. Rapport 2010 sur la prise en charge médicale des personnes infectées par le VIH-Ministère des Affaires sociales et de la Santé [in French]. Available at: http://www.sante.gouv.fr/IMG/pdf/ Rapport-2010-sur-la-prise-en-charge-medicale-des-personnes-infectees-par-le-VIH- sous-la-direction-du-Pr-Patrick-Yeni.pdf. Accessed 15 February 2013.
2. European AIDS Clinical Society (EACS). Guidelines for the clinical management and treatment of HIV-infected adults, version October 2011; pp 1-61. Available at: http://www.europeanaidsclinicalsociety. org/images/stories/EACS- Pdf/EacsGuidelines-v6.1-2edition.pdf. Accessed 15 February 2013.
3. AIDSInfo. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available at: http://aidsinfo.nih.gov/ contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed 15 February 2013.
4. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29:484-94.
5. Warszawski J, Tubiana R, Le Chenadec J, et al. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS 2008; 22:289-99.
6. Townsend CL, Cortina-Borja M, Peckham CS, De Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008; 22:973-81.
7. Azria E, Moutafoff C, Schmitz T, et al. Pregnancy outcomes in women with HIV type-1 receiving a lopinavir/ritonavir-containing regimen. Antivir Ther 2009; 14:423-32.
8. Heidari S, Mofenson L, Cotton MF, Marlink R, Cahn P, Katabira E. Antiretroviral drugs for preventing mother-to-child transmission of HIV: a review of potential effects on HIV-exposed but uninfected children. J Acquir Immune Defic Syndr 2011; 57:290-6.
9. Wutzler P, Thust R. Genetic risks of antiviral nucleoside analogues-a survey. Antiviral Res 2001; 49:55-74.
10. Seier T, Zilberberg G, Zeiger DM, Lovett ST. Azidothymidine and other chain terminators are mutagenic for template-switch-generated genetic mutations. Proc Natl Acad Sci USA 2012; 109:6171-4.
11. World Health Organization. International Agency for Research on Cancer. Monographs of the evaluation of carcinogenic risk for human. 2000; 76:73-127.
12. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331:1173-80.
13. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354:1084-9.
14. Brogly SB, Ylitalo N, Mofenson LM, et al. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. AIDS 2007; 21:929-38.
15. Le Chenadec J, Mayaux M-J, Guihenneuc-Jouyaux C, Blanche S. Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants. AIDS 2003; 17:2053-61.
16. Lipshultz SE, Shearer WT, Thompson B, et al. Cardiac effects of antiretroviral therapy in HIV-negative infants born to HIV-positive mothers: NHLBI CHAART-1 (National Heart, Lung, and Blood Institute Cardiovascular Status of HAART Therapy in HIV-Exposed Infants and Children cohort study). J Am Coll Cardiol 2011; 57: 76-85.
17. Cade WT,Waggoner AD, Hubert S, Krauss MJ, Singh GK, Overton ET. Reduced diastolic function and left ventricular mass in HIV-negative preadolescent children exposed to antiretroviral therapy in utero. AIDS 2012; 26:2053-8.
18. Brogly SB, DiMauro S, Van Dyke RB, et al. Short communication: transplacental nucleoside analogue exposure and mitochondrial parameters in HIV-uninfected children. AIDS Res Hum Retroviruses 2011; 27:777-83.
19. Olivero OA. Relevance of experimental models for investigation of genotoxicity induced by antiretroviral therapy during human pregnancy. Mutat Res 2008; 658:184-90.
20. Briand N, Mandelbrot L, Blanche S, et al. Previous antiretroviral therapy for prevention of mother-to-child transmission of HIV does not hamper the initial response to PI-based multitherapy during subsequent pregnancy. J Acquir Immune Defic Syndr 2011; 57:126-35.
21. Garrett NJ, Matin N, Edwards SG, Miller RF. Efficacy of boosted protease inhibitor monotherapy in patients with complex medical problems. AIDS 2007; 21:1821-3.
22. Delfraissy J-F, Flandre P, Delaugerre C, et al. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS 2008; 22:385-93.
23. Ghosn J, Flandre P, Cohen-Codar I, et al. Long-term (96-week) followup of antiretroviral-naive HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial*. HIV Med 2010; 11:137-42.
24. Katlama C, Valantin MA, Algarte-Genin M, et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS 2010; 24:2365-74.
25. Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment ( placenta and amniotic fluid). Antivir Ther 2011; 16:1139-47.
26. AIDS Clinical Trials Group. Division of AIDS table for grading the severity of adult and pediatric adverse events. Rockville, MD: National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS, 2004.
27. Bunupuradah T, Chetchotisakd P, Ananworanich J, et al. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study. Antivir Ther 2012; 17: 1351-61.
28. Weinberg A, Harwood JEF, McFarland EJ, et al. Kinetics and determining factors of the virologic response to antiretrovirals during pregnancy [published online ahead of print 10 January 2010]. Infect Dis Obstet Gynecol 2009; doi:10.1155/2009/621780.
29. Read PJ, Mandalia S, Khan P, et al. When should HAART be initiated in pregnancy to achieve an undetectable HIV viral load by delivery? AIDS 2012; 26:1095-103.
30. Taylor GP, Clayden P, Dhar J, et al. British HIV Association guidelines for the management of HIV infection in pregnant women 2012. HIV Med 2012; 13(suppl 2):87-157.
31. Rachas A,Warszawski J, Le Chenadec J, et al. Does pregnancy affect the early response to cART? AIDS 2013; 27:357-67.
32. Tubiana R, Le Chenadec J, Rouzioux C, et al. Factors associated with mother-to-child transmission of HIV-1 despite amaternal viral load 500 copies/ml at delivery: a case-control study nested in the French perinatal cohort (EPF-ANRS CO1). Clin Infect Dis, 2010, 50, 585-96.
33. Parkin NT, Hellmann NS, Whitcomb JM, Kiss L, Chappey C, Petropoulos CJ. Natural variation of drug susceptibility in wild-type human immunodeficiency virus type. Antimicrob Agents Chemother 2004; 48:437-43.
34. Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. AIDS 2006; 20:1931-9.
35. Best BM, Stek AM, Mirochnick M, et al. Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J Acquir Immune Defic Syndr 2010; 54:381-8.
36. Gavard L, Gil S, Peytavin G, et al. Placental transfer of lopinavir/ritonavir in the ex vivo human cotyledon perfusion model. Am J Obstet Gynecol 2006; 195:296-301.
37. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1996; 335:1621-9.
38. Mandelbrot L, Burgard M, Teglas JP, et al. Frequent detection of HIV-1 in the gastric aspirates of neonates born to HIV-infected mothers. AIDS 1999; 13:2143-9.